Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
128 hedge funds and large institutions have $545M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 46 increasing their positions, 38 reducing their positions, and 15 closing their positions.
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
34% more capital invested
Capital invested by funds: $408M → $545M (+$137M)
21% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 38
4% more funds holding
Funds holding: 123 → 128 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$31.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$16.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$13.2M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$10.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$20M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.3M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$10.2M |
| 4 |
AC
Armistice Capital
New York
|
-$4.81M |
| 5 |
JP Morgan Chase
New York
|
-$3.55M |
DCPH Hedge Fund Activity: Q2 2022 in Review
128 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2022, worth a combined $545M — up 34% from $408M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new DCPH positions and 15 closed out — a net gain of 7 holders — while 46 added to existing stakes and 38 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $31.6M. The largest seller was State Street, cutting an estimated $20M.
- 128 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2022, up from 123 in Q1 2022.
- Funds reported $545M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2022, up 34% quarter-over-quarter.
- 22 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 15 closed out, a net change of +7 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Goldman Sachs, an estimated $31.6M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was State Street, an estimated $20M sold.
Based on aggregated 13F filings for Q2 2022.